

<b>National Imaging Associates, Inc.*</b>	
<b>Clinical guidelines</b> <b>ENDOMETRIAL CANCER</b>	<b>Original Date: June 2013</b>
<b>Radiation Oncology</b>	<b>Last Revised Date: February 2020</b>
<b>Guideline Number: NIA_CG_129</b>	<b>Implementation Date: January 2021</b>

### INDICATIONS FOR RADIATION THERAPY AND TREATMENT OPTIONS:

#### Post-operative (NCCN, 2019)

- Brachytherapy Only (HDR or LDR, 5 fx maximum)
  - Stage IA – with adverse risk factors
  - Stage IA – without risk factors (Grades G2, 3)
  - Stage IB
  - Stage II – (Grade G1)
- External Beam Radiation Therapy Only (2D, 3D-CRT, 45-50.4 Gy, 28 fx maximum)
  - Stage IA – with adverse risk factors (Grades G2, 3)
  - Stage IB – without adverse risk factors (Grade G3)
  - Stage IB – with risk factors
  - Stage II – (Grade G1)
  - Stage III
  - Stage IV
- External Beam (2D, 3D-CRT, 45-50 Gy, 28 fx maximum) and Brachytherapy (HDR or LDR, 5 fx maximum)
  - Stage IA – with adverse risk factors (Grades G2, 3)
  - Stage IB – without risk factors (Grade G3)
  - Stage IB – with risk factors
  - Stage II – (Grades G1, 2, 3)
  - Stage IIIA & IIIB & IIIC (Grades G1, 2, 3)

#### Medically Inoperable/ Pre-Operative

- Brachytherapy Only (HDR or LDR, 7 fx maximum)
  - Stage I & II
- External Beam Radiation Therapy Only (2D, 3D-CRT, 45-50 Gy, 28 fx maximum)
  - All Stages
- External Beam (2D, 3D-CRT, 45-50.4 Gy) and Brachytherapy (HDR or LDR, 4 fx maximum)
  - All Stages

\* National Imaging Associates, Inc. (NIA) is a subsidiary of Magellan Healthcare, Inc.

## **Palliative**

- Up to 10 fx

*Unless otherwise indicated standard radiation fractionation consists of 1.8 Gy to 2.0 Gy per day.*

## **TREATMENT OPTIONS REQUIRING ADDITIONAL CLINICAL REVIEW:**

### **Intensity Modulated Radiation Therapy (IMRT)**

IMRT is not indicated as a standard treatment option and should not be used routinely for the delivery of radiation therapy for endometrial cancer (NCCN, 2019). IMRT is strictly defined by the utilization of inverse planning modulation techniques. IMRT may be appropriate for limited circumstances in which radiation therapy is indicated and 3D conformal radiation therapy (3D-CRT) techniques cannot adequately deliver the radiation prescription without exceeding normal tissue radiation tolerance, the delivery is anticipated to contribute to potential late toxicity or tumor volume dose heterogeneity is such that unacceptable hot or cold spots are created.

Clinical rationale and documentation for performing IMRT rather than 2D or 3D-CRT treatment planning and delivery will need to:

- Demonstrate how 3D-CRT isodose planning cannot produce a satisfactory treatment plan (as stated above) via the use of a patient specific dose volume histograms and isodose plans.
- Provide tissue constraints for both the target and affected critical structures.

### **Stereotactic Body Radiation Therapy (SBRT)**

Stereotactic Body Radiation Therapy is not a standard treatment option for the treatment of endometrial cancer.

### **Proton Beam Radiation Therapy**

Proton beam is not an approved treatment option for endometrial cancer. Proton beam has not been proven superior treatment to conventional radiation therapy (NCCN, 2019).

## **THE FOLLOWING APPLIES TO CMS (MEDICARE) MEMBERS ONLY:**

*For Proton Beam and Stereotactic Radiotherapy refer to Local Coverage Determination (LCD), if applicable.*

---

## **BACKGROUND:**

The majority of endometrial cancers are adenocarcinomas, with uterine sarcomas accounting for <10%. This clinical guideline will focus primarily on adenocarcinoma of the endometrium.

After a diagnosis of endometrial cancer is made, it is followed by a staging evaluation to determine extent of disease (local, regional, or metastatic) and prognostic findings. For patients in whom cancers of the uterus are suspected, an endometrial biopsy is typically performed (NCCN, 2019). A review of the pathology will determine whether or not the tumors are of epithelial origin (endometrioid, papillary serous, clear cell, or carcinosarcoma) or stromal/mesenchymal carcinoma (stromal sarcoma or leiomyosarcoma). The majority of endometrial cancers, however, are adenocarcinomas with tumor typically confined to the uterus. Thus, this disease is often

localized with an excellent prognosis. Current workup, including a complete surgical assessment, includes a histological grade, depth of myometrial invasion, and extent of extrauterine involvement. Prognostic factors are based on a pathologic assessment and include the percent of myometrial invasion, myometrial thickness, tumor size and location (upper fundus or lower uterine cervical), cervix involvement, and lymphovascular space involvement. The majority of patients are treated surgically with radiation reserved for patients who are deemed at a high risk of recurrence or for those deemed medically inoperable (Klopp, 2014)

This guideline outlines several methods suitable for the employment of radiation therapy. This includes the use of 3-dimensional conformal radiation therapy and/or internal radiation (brachytherapy). IMRT is not indicated as a standard treatment option for uterine cancer. External beam treatments are typically delivered using a high-energy linear accelerator. Brachytherapy is generally delivered using temporary HDR sources such as iridium 192. The purpose of this guideline is to outline the most efficient, comparatively effective, diagnostic and treatment pathway. Treatment is typically broken down into patients in whom disease is limited to the uterus, cervical involvement (either suspected or confirmed), or extrauterine disease (Elshaikh, 2014).

**POLICY HISTORY:**

**Review Date:** February 2019

**Review Summary:** Added and updated references

**Review Date:** February 2020

**Review Summary:** Updated references

## REFERENCES:

Alektiar KM, Venkatraman E, Chi DS, et al. Intravaginal brachytherapy alone for intermediate risk endometrial cancer. *Int J Radiat Oncol Biol Phys*. 2005; 62(1):111-117. doi:10.1016/j.ijrobp.2004.09.054.

American College of Radiology (ACR). ACR Appropriateness Criteria®. Advanced Stage Endometrial Cancer. <https://acsearch.acr.org/docs/3083084/Narrative/>. Published 2014. Accessed June 12, 2015.

ASTEC/EN.5 Study Group, Blake P, Swart AM, et al. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomized trials): Pooled trial results, systematic review, and meta-analysis. *Lancet*. 2009; 373(9658):137-146. doi: 10.1016/S0140-6736(08)61767-5.

American Society for Radiation Oncology (ASTRO). Ten Things Physicians and Patients Should Question. Keyword: Endometrial. Choosing Wisely®. [http://www.choosingwisely.org/clinician-lists/#keyword=Endometrial&parentSociety=American\\_Society\\_for\\_Radiation\\_Oncology](http://www.choosingwisely.org/clinician-lists/#keyword=Endometrial&parentSociety=American_Society_for_Radiation_Oncology). Released September 15, 2014. Accessed May 15, 2017.

American Society for Therapeutic Radiology and Oncology (ASTRO). Cervical and endometrial cancer patients report fewer side effects and better quality of life with IMRT. [https://www.astro.org/uploadedFiles/\\_MAIN\\_SITE/News\\_and\\_Publications/News/News\\_Releases/2016/ASTRO\\_2016\\_Klopp.pdf](https://www.astro.org/uploadedFiles/_MAIN_SITE/News_and_Publications/News/News_Releases/2016/ASTRO_2016_Klopp.pdf). Published September 26, 2016. Accessed on May 15, 2017.

Bentzen SM, Constine LS, Deasy JO, et al. Quantitative analyses of normal tissue effects in the clinic QUANTEC: An introduction to the scientific issues. Introductory paper. *Int J Radiat Oncol Biol Phys*. 2010; 76(3):S3-S9.

Creutzberg CL, Van Putten WL, Warlam-Rodenhuis CC, et al. Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: The postoperative radiation therapy endometrial carcinoma trial. *J Clin Oncol*. 2004; 22:1234-1241. doi: 10.1200/JCO.2004.08.159.

Elshaikh MA, Yashar CM, Wolfson AH, et al. ACR Appropriateness Criteria: Advanced stage endometrial cancer. American College of Radiology; 2014. Retrieved from <https://acsearch.acr.org/docs/3083084/Narrative/> Accessed February 11, 2019.

Homesley HD, Filiaci V, Gibbons SK, et al. A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a gynecologic oncology group study [SGO abstract 1]. Presented at: 39<sup>th</sup> Annual Meeting of the Society of Gynecologic Oncologists; March 9, 2008: Tampa, FL. *Gynecol Oncol*. 2009; 108:S2.

Jackson A, Marks LB, Bentzen SM, et al. The lessons of QUANTEC: Recommendations for reporting and gathering data on dose-volume dependencies of treatment outcome. *Int J Radiat Oncol Biol Phys*. 2010; 76(3):S155-S160.

Johnson N, Comes P. Survival and recurrent disease after postoperative radiotherapy for early endometrial cancer: Systematic review and meta-analysis. *BJOG*. 2007; 114(11): 1313-1320. doi: 10.1111/j.1471-0528.2007.01332.x.

Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a gynecologic oncology group study. *Gynecol Oncol*. 2004; 92:744-751. <http://dx.doi.org/10.1016/j.ygyno.2003.11.048>.

Kim DH, Lee JH, Ki YK, et al. Short-course palliative radiotherapy for uterine cervical cancer. *Radiat Oncol J*. December 2013; 31(4):216-221. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3912235/>. Accessed on April 25, 2018.

Klopp A, Smith BD, Alektiar K, et al. The role of postoperative radiation therapy for endometrial cancer: an ASTRO evidence-based guideline. [Published online ahead of print March 31, 2014a]. *Pract Radiat Oncol*. May/June 2014; 4(3):137-144. doi: 10.1016/j.pro.2014.01.003. Accessed on April 25, 2018.

Klopp A, Smith BD, Alektiar K, et al. The role of postoperative radiation therapy for endometrial cancer: An ASTRO evidence-based guideline. *Practical Radiation Oncology*. 2014b; Suppl. <https://www.practicalradonc.org/cms/attachment/2014676400/2036188629/mmc1.pdf?code=pro-site>. Accessed June 2, 2015.

Kong A, Johnson N, Comes P, et al. Adjuvant radiotherapy for stage I endometrial cancer. *Cochrane Database Syst Rev*. 2007; (2):CD003916.

Kong A, Powell M, Blake P. The role of postoperative radiotherapy in carcinoma of the endometrium. *Clin Oncol (R Coll Radiol)*. 2008; 20(6):457-462. <http://dx.doi.org/10.1016/j.clon.2008.03.011>.

Lee CM, Szabo A, Shrieve DC, et al. Frequency and effect of adjuvant radiation therapy among women with stage I endometrial adenocarcinoma. *JAMA*. 2006; 295:389-397. doi:10.1001/jama.295.4.389.

National Comprehensive Cancer Network (NCCN). Uterine Neoplasms V1. [https://www.nccn.org/professionals/physician\\_gls/pdf/uterine.pdf](https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf). Published 2018. Retrieved April 25, 2018.

National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology: Uterine neoplasms. V 2.2019. NCCN; Fort Washington, PA. Retrieved from [https://www.nccn.org/professionals/physician\\_gls/pdf/uterine.pdf](https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf). Accessed February 11, 2019.

Nout RA, Putter H, Jurgenliemk-Schulz IM, et al. Vaginal brachytherapy versus external beam pelvic radiotherapy for high-intermediate risk endometrial cancer. Results of the randomized PORTEC-2 trial [abstract]. *J Clin Oncol*. 2008; 26 Suppl 15. doi: 10.1016/S0140-6736(09)62163-2.


Portelance L, Moughan J, Jhingran A, et al. A phase II multi-institutional study of postoperative pelvic Intensity Modulated Radiation Therapy (IMRT) with weekly Cisplatin in patients with cervical carcinoma: two year efficacy results of the RTOG 0418. Proceedings of the American Society for Radiation Oncology 54th Annual Meeting. *Int J Radiat Oncol Biol Phys*. October 1, 2011; 81 Suppl 2:S3. doi: <https://doi.org/10.1016/j.ijrobp.2011.06.007>.

Scholten AN, Van Putten WL, Beerman H, et al. PORTEC study group postoperative radiotherapy for stage I endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review. *Int J Radiat Oncol Biol Phys*. 2005; 63(3):834-838. doi:10.1016/j.ijrobp.2005.03.007.

Shih KK, Milgrom SA, Abu-Rustum NR, et al. Postoperative pelvic intensity-modulated radiotherapy in high risk endometrial cancer. [Published online ahead of print November 20, 2012]. *Gynecol Oncol.* 2013; 128(3):535-539. doi: 10.1016/j.ygyno.2012.11.020.

Solhjem MC, Petersen IA, Haddock MG. Vaginal brachytherapy alone is sufficient adjuvant treatment of surgical stage I endometrial carcinoma. *Int J Radiat Oncol Biol Phys.* 2005; 62(5):1379-1384. doi:10.1016/j.ijrobp.2005.01.026.

Susumu N, Sagae S, Udagawa Y, et al. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate and high risk endometrial cancer: A Japanese gynecologic oncology group study. *Gynecol Oncol.* 2008; 108(1):226-233. <http://dx.doi.org/10.1016/j.ygyno.2007.09.029>.

Reviewed / Approved by  Sri Gorty, M.D., Physician Clinical Reviewer, Radiation Oncology

**Disclaimer:** Magellan Healthcare service authorization policies do not constitute medical advice and are not intended to govern or otherwise influence the practice of medicine. These policies are not meant to supplant your normal procedures, evaluation, diagnosis, treatment and/or care plans for your patients. Your professional judgement must be exercised and followed in all respects with regard to the treatment and care of your patients. These policies apply to all Magellan Healthcare subsidiaries including, but not limited to, National Imaging Associates (“Magellan”). The policies constitute only the reimbursement and coverage guidelines of Magellan. Coverage for services varies for individual members in accordance with the terms and conditions of applicable Certificates of Coverage, Summary Plan Descriptions, or contracts with governing regulatory agencies. Magellan reserves the right to review and update the guidelines at its sole discretion. Notice of such changes, if necessary, shall be provided in accordance with the terms and conditions of provider agreements and any applicable laws or regulations.